lenalidomide,rituximab,acalabrutinib
Not Tagged
['lymsm']
orr 100%, 83% cr. tp53 still relapsing after induction. therapy was 'tolerable' despite high incidence of many aes. mrd-adapted deescalation is definitely interesting in standard-risk disease, but jury still out re: high risk. #ash22 #lymsm 
#lymsm & #mmsm hematologist & patient-reported outcomes researcher @CUHematology. Founder of https://t.co/kN6qeGXfg5, @inTrainingDoc & @inHouseMag. ??????